Clinical trials: Metastatic
Liver Cancer
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00867321
- Testing
- bevacizumab, sorafenib tosylate
- Where
- 177 sites in United States
- Volunteers
- 24 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
- Trial name
- NCT02179671
- Testing
- Gefitinib, AZD9291, Selumetinib+Docetaxel
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Melanoma
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in…
- Trial name
- RELATIVITY-127 (NCT05625399)
- Testing
- Nivolumab + Relatlimab, rHuPH20
- Where
- 149 sites in United States, Australia and 17 more
- Volunteers
- 579 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Cancer
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00509665
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Neoplasm Metastasis
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03383692
- Testing
- DS-8201a, Ritonavir, Itraconazole
- Where
- 10 sites in Japan, South Korea and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Metastatic Breast Cancer, Breast Carcinoma
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
The purpose of this study is to examine the safety and efficacy of Ruxolitinib in combination with Trastuzumab in treatment of HER2 positive metastatic breast cancer.
- Conditions
- Metastatic Breast Cancer, Breast Carcinoma, HER-2 Positive Breast Cancer
- Trial name
- NCT02066532
- Testing
- Ruxolitinib, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dawn L. Hershman
HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain.
- Trial name
- NCT03417544
- Testing
- ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Nancy Lin, MD
Neoplasms
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
This is a study in adults with advanced cancer (solid tumours) in whom previous treatment was not successful. The study tests 2 medicines called BI 1387446 and BI 754091. Both medicines may help the immune system fight cancer.
- Trial name
- NCT04147234
- Testing
- BI 1387446 50 μg, BI 754091, BI 1387446 100 μg
- Where
- 8 sites in United States, Spain and 1 more
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, floxuridine, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00449163
- Testing
- Bevacizumab, Floxuridine, Irinotecan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami
Colon Cancer, Colorectal Cancer
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
This study is for people with advanced colorectal cancer. This study uses the drugs Celebrex and EPO906. EPO906 is an experimental drug that has not been approved by the FDA.
- Trial name
- NCT00159484
- Testing
- EPO906, Celecoxib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Southern California
Melanoma, Cancer
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Primary objective: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment.
- Trial name
- NCT00613509
- Testing
- ALVAC(2) Melanoma multi-antigen therapeutic vaccine, Intron A, Interferon alpha -2b
- Where
- 19 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Prostate Cancer, Prostate Adenocarcinoma
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Trial name
- CONDOR (NCT03739684)
- Testing
- 18F-DCFPyL, PET/CT Imaging
- Where
- 14 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Multiple Sclerosis, Secondary Progressive
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive…
- Trial name
- INSPIRE (NCT02430532)
- Testing
- dimethyl fumarate
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 58 people
- Sponsor
- Biogen
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or…
- Trial name
- NCT02457793
- Testing
- Cobimetinib, GDC-0994
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase II trial studies how well decitabine and total-body irradiation followed by donor bone marrow transplant and cyclophosphamide works in treating patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01707004
- Testing
- decitabine, fludarabine phosphate, busulfan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
The purpose of this study is to determine the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple negative breast cancer…
- Conditions
- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
- Trial name
- NCT04674306
- Testing
- α-lactalbumin vaccine, Zymosan
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- George T. Budd
Cognitive/Functional Effects, Metastatic Cancer
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00566852
- Testing
- Memantine, Whole brain radiation therapy
- Where
- 235 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Radiation Therapy Oncology Group
Cancer
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
This is a Phase IIa, open-label, single-arm, multi-center study to evaluate the efficacy and safety of orally administered MEK inhibitor trametinib as the second line in subjects with advanced or metastatic biliary tract cancers…
- Trial name
- NCT01943864
- Testing
- Trametinib (single tablet), Trametinib (Multiple tablet)
- Where
- 5 sites in Japan
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.